{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T08:32:30Z","timestamp":1720773150312},"reference-count":34,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.3892\/mmr.2014.2333","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T15:00:04Z","timestamp":1402930804000},"page":"1519-1524","source":"Crossref","is-referenced-by-count":4,"title":["Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr\/Abl-dependent mechanisms"],"prefix":"10.3892","volume":"10","author":[{"given":"WENBIN","family":"XU","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WEI","family":"WEI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"QING","family":"YU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHAO","family":"WU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CHENJING","family":"YE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YINGLI","family":"WU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HUA","family":"YAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2014,6,16]]},"reference":[{"key":"key20180108010017_b1-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/sj.leu.2402879","article-title":"Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1)","volume":"17","author":"Schiffer","year":"2003","journal-title":"Leukemia"},{"key":"key20180108010017_b2-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/sj.onc.1203467","article-title":"The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6\/Abl) have altered substrate preferences and activate similar intracellular signalling pathways","volume":"19","author":"Voss","year":"2000","journal-title":"Oncogene"},{"key":"key20180108010017_b3-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1038\/sj.onc.1203484","article-title":"JAK-STAT signaling activated by Abl oncogenes","volume":"19","author":"Danial","year":"2000","journal-title":"Oncogene"},{"key":"key20180108010017_b4-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0301-472X(03)00069-9","article-title":"Mechanisms of Bcr-Abl-mediated NF-kappaB\/Rel activation","volume":"31","author":"Kirchner","year":"2003","journal-title":"Exp Hematol"},{"key":"key20180108010017_b5-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1182\/blood.V86.3.1148.1148","article-title":"BCR-ABL-mediated inhibition of apoptosis with delay of G2\/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents","volume":"86","author":"Bedi","year":"1995","journal-title":"Blood"},{"key":"key20180108010017_b6-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.cdd.4401210","article-title":"Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity","volume":"10","author":"Bueno-da-Silva","year":"2003","journal-title":"Cell Death Differ"},{"key":"key20180108010017_b7-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/sj.onc.1201664","article-title":"Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL","volume":"16","author":"Amarante-Mendes","year":"1998","journal-title":"Oncogene"},{"key":"key20180108010017_b8-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/sj.leu.2404278","article-title":"Proteasome inhibitor bortezomib for the treatment of multiple myeloma","volume":"20","author":"Cavo","year":"2006","journal-title":"Leukemia"},{"key":"key20180108010017_b9-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ncponc0555","article-title":"Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies","volume":"3","author":"Caravita","year":"2006","journal-title":"Nat Clinl Pract Oncol"},{"key":"key20180108010017_b10-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1182\/blood-2003-12-4121","article-title":"Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr\/Abl-dependent and -independent mechanisms","volume":"104","author":"Dai","year":"2004","journal-title":"Blood"},{"key":"key20180108010017_b11-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2003-03-0737","article-title":"The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr\/Abl+ cells sensitive and resistant to STI571","volume":"102","author":"Yu","year":"2003","journal-title":"Blood"},{"key":"key20180108010017_b12-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1182\/blood.V89.9.3354","article-title":"Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients","volume":"89","author":"Shen","year":"1997","journal-title":"Blood"},{"key":"key20180108010017_b13-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood.V88.3.1052.1052","article-title":"In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha\/PML proteins","volume":"88","author":"Chen","year":"1996","journal-title":"Blood"},{"key":"key20180108010017_b14-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2005-08-3532","article-title":"Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity","volume":"107","author":"Mathews","year":"2006","journal-title":"Blood"},{"key":"key20180108010017_b15-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V95.3.1014.003k04_1014_1022","article-title":"Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L)","volume":"95","author":"Perkins","year":"2000","journal-title":"Blood"},{"key":"key20180108010017_b16-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/sj.leu.2402104","article-title":"Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells","volume":"15","author":"Porosnicu","year":"2001","journal-title":"Leukemia"},{"key":"key20180108010017_b17-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.febslet.2006.12.016","article-title":"Involvement of a Rho-ROCK-JNK pathway in arsenic trioxide-induced apoptosis in chronic myelogenous leukemia cells","volume":"581","author":"Potin","year":"2007","journal-title":"FEBS Lett"},{"key":"key20180108010017_b18-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/sj.leu.2404735","article-title":"Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta","volume":"21","author":"Yan","year":"2007","journal-title":"Leukemia"},{"key":"key20180108010017_b19-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.freeradbiomed.2009.12.022","article-title":"Reactive oxygen species, cellular redox systems, and apoptosis","volume":"48","author":"Circu","year":"2010","journal-title":"Free Radic Biol Med"},{"key":"key20180108010017_b20-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1073\/pnas.0306687101","article-title":"Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells","volume":"101","author":"Chou","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108010017_b21-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s12032-011-9920-1","article-title":"Assessment of the involvement of oxidative stress and Mitogen-Activated Protein Kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on human leukemic cell lines","volume":"29","author":"Stepnik","year":"2012","journal-title":"Med Oncol"},{"key":"key20180108010017_b22-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"key20180108010017_b23-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/sj.leu.2403764","article-title":"Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL - Inhibition of P-glycoprotein function by 17-AAG","volume":"19","author":"Radujkovic","year":"2005","journal-title":"Leukemia"},{"key":"key20180108010017_b24-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbrc.2010.12.111","article-title":"Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR\/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1","volume":"405","author":"Li","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"key20180108010017_b25-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.leukres.2009.05.024","article-title":"Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition","volume":"34","author":"Wen","year":"2010","journal-title":"Leuk Res"},{"key":"key20180108010017_b26-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.cancergencyto.2010.02.010","article-title":"Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders","volume":"199","author":"Canestraro","year":"2010","journal-title":"Cancer Gene Cytogenet"},{"key":"key20180108010017_b27-mmr-10-03-1519","first-page":"794","article-title":"Synergistic effects of arsenic trioxide and proteasome inhibitor bortezomib on apoptosis induction in Raji cell line","volume":"16","author":"He","year":"2008","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"key20180108010017_b28-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.cdd.4400545","article-title":"Butyrate mediates Caco-2 cell apoptosis via up-regulation of pro-apoptotic BAK and inducing caspase-3 mediated cleavage of poly-(ADP-ribose) polymerase (PARP)","volume":"6","author":"Ruemmele","year":"1999","journal-title":"Cell Death Differ"},{"key":"key20180108010017_b29-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1023\/A:1009623222534","article-title":"Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells","volume":"5","author":"Fernandez-Luna","year":"2000","journal-title":"Apoptosis"},{"key":"key20180108010017_b30-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1600-0609.2008.01199.x","article-title":"Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients","volume":"82","author":"Bianchini","year":"2009","journal-title":"Eur J Haematol"},{"key":"key20180108010017_b31-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1007\/s10495-013-0854-2","article-title":"Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-\u03baB inhibition and Bcr\/Abl protein deletion","volume":"18","author":"Wei","year":"2013","journal-title":"Apoptosis"},{"key":"key20180108010017_b32-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"24273","DOI":"10.1074\/jbc.M002094200","article-title":"The BCR\/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells","volume":"275","author":"Sattler","year":"2000","journal-title":"J Biol Chem"},{"key":"key20180108010017_b33-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1038\/onc.2011.156","article-title":"NF-\u03baB suppresses ROS levels in BCR-ABL(+) cells to prevent activation of JNK and cell death","volume":"30","author":"Stein","year":"2011","journal-title":"Oncogene"},{"key":"key20180108010017_b34-mmr-10-03-1519","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/leu.2009.49","article-title":"Bcr-Abl-mediated redox regulation of the PI3K\/AKT pathway","volume":"23","author":"Naughton","year":"2009","journal-title":"Leukemia"}],"container-title":["Molecular Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/mmr.2014.2333\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:59:51Z","timestamp":1597971591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mmr.2014.2333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,16]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,6,16]]},"published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.3892\/mmr.2014.2333"],"URL":"https:\/\/doi.org\/10.3892\/mmr.2014.2333","relation":{},"ISSN":["1791-2997","1791-3004"],"issn-type":[{"value":"1791-2997","type":"print"},{"value":"1791-3004","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,16]]}}}